ERBB2 and breast carcinoma: The present study is a phase III clinical trial aimed to compare the efficacy, safety, and immunogenicity of TA4415V (registered as AryoTrust in Iran) with the reference drug (Herceptin, Genentech, USA) in HER2-positive early-stage breast cancer patients.